Patients with symptoms like nasal blockage, secretion and loss of smell, have reduced quality of life. Worldwide research has focused on which patients develop chronic disease, and which treatments are most effective. We have contributed to this research with an epidemiological study on prevalence and severity of chronic rhinosinusitis on Funen.
Further, we have evaluated the efficacy of sinus surgery. We are currently involved in a national Danish study (Global airways) on the use of biological treatment for chronic rhinosinusitis: Which treatment is best suited for which types of patients?
Another important project is on the chronicity of chronic rhinosinusitis. In this project we follow newly diagnosed patients with chronic rhinosinusitis. We evaluate our patients using the Galenus health app which also helps us educating our patients this also enables us to predict markers progression of the disease.
We strive to improve nasal breathing and sinus disease in our patients and to develop educational tools that improve the patient- and doctor education.
Our goal is to perform treatments, both surgical and medical, with high quality and to continuously improve our patient care.
HHT- Hereditary Haemorrhagic Telangiektasia
This is a rare dominantly inherited disease around 800 Danes suffer from this disease. The Danish HHT center is situated at Odense University Hospital, and The Chair is Professor in Rhinology and Vascular malformations PhD Anette Drøhse Kjeldsen.
We are member of the European reference network VASCERN, as well as the international patient organization Cure HHT. And are of cause in close collaboration with the Danish HHT patient organization: Osler.dk.
Through our work we have developed treatment and screening options for this rare disease, and we are proud to say that the patients are very satisfied with our work, now they have a place to go to get treatment and advice, as well as updated information on this rare disease.
Currently we focus on the neurological consequences of having HHT as well as the consequences of having vascular malformations in the liver and in the GI tract.
We continuously evaluate current treatment strategies for the severe epistaxis, and we participate in developing new strategies. On top of this we have tight collaboration with our department of clinical genetics as well as department of radiology, medical gastroenterology, neurosurgery, cardiology, pediatrics, and other departments when needed.
Our Goal is to continuously be among the European top centers taking care regarding all aspects of HHT
